Analysts Offer Predictions for Kura Oncology, Inc.’s Q1 2023 Earnings (NASDAQ:KURA)

Kura Oncology, Inc. (NASDAQ:KURAGet Rating) – Investment analysts at Wedbush issued their Q1 2023 EPS estimates for Kura Oncology in a research note issued on Thursday, August 4th. Wedbush analyst R. Driscoll expects that the company will post earnings of ($0.55) per share for the quarter. Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.16) per share. Wedbush also issued estimates for Kura Oncology’s Q2 2023 earnings at ($0.55) EPS, Q3 2023 earnings at ($0.56) EPS, Q4 2023 earnings at ($0.56) EPS, FY2025 earnings at $2.41 EPS and FY2026 earnings at $5.88 EPS.

Kura Oncology (NASDAQ:KURAGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.03. During the same quarter in the previous year, the firm earned ($0.46) EPS.

Other analysts have also recently issued reports about the stock. Credit Suisse Group upped their target price on shares of Kura Oncology from $27.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, July 13th. Cantor Fitzgerald started coverage on shares of Kura Oncology in a report on Tuesday, July 12th. They set an “overweight” rating and a $30.00 target price for the company. Finally, StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, May 18th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and an average price target of $37.50.

Kura Oncology Stock Up 2.7 %

KURA opened at $15.49 on Friday. Kura Oncology has a twelve month low of $10.41 and a twelve month high of $21.19. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -7.75 and a beta of 0.92. The firm has a 50 day moving average price of $15.96 and a 200-day moving average price of $14.97.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. Deep Track Capital LP bought a new position in shares of Kura Oncology during the fourth quarter worth $35,700,000. Deerfield Management Company L.P. Series C boosted its position in shares of Kura Oncology by 51.8% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,513,756 shares of the company’s stock worth $49,193,000 after acquiring an additional 1,198,339 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Kura Oncology by 222.0% during the first quarter. Assenagon Asset Management S.A. now owns 1,680,196 shares of the company’s stock worth $27,018,000 after acquiring an additional 1,158,356 shares during the last quarter. Suvretta Capital Management LLC boosted its position in shares of Kura Oncology by 45.2% during the fourth quarter. Suvretta Capital Management LLC now owns 3,572,419 shares of the company’s stock worth $50,014,000 after acquiring an additional 1,112,217 shares during the last quarter. Finally, Aaron Wealth Advisors LLC boosted its position in shares of Kura Oncology by 1,503.0% during the first quarter. Aaron Wealth Advisors LLC now owns 910,690 shares of the company’s stock worth $56,635,000 after acquiring an additional 853,877 shares during the last quarter. Institutional investors own 94.65% of the company’s stock.

Kura Oncology Company Profile

(Get Rating)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.

Featured Stories

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Want More Great Investing Ideas?

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.